Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 20, 2015Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIVCard Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*
Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.**...
-
Jan 15, 2015•The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
Paris, January 15, 2015 – The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the...
- Dec 5, 2014-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --
Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...
- Nov 6, 2014Celebrity Animal Behaviorist Brandon McMillan Joins Eisai, Epilepsy Foundation and 4 Paws for Ability to Shed Light on How Dogs Can Provide Functional and Emotional Support
Eisai Inc. today announced the launch of Magnolia™ Paws for Compassion™, a new program created to raise awareness of the beneficial impact that animals can have on people living with epilepsy...
-
Nov 6, 2014-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...
-
Nov 3, 2014-- Trial Met Primary Efficacy Endpoint with Statistical Significance After 12 Weeks of Treatment --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking...
-
Oct 31, 2014-- Results of Investigational Study of Coadministration of Lorcaserin and Phentermine Accepted as Late Breaking Poster --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the...
-
Oct 28, 2014-- Trial Met Primary Safety Objective After 12 Weeks of Treatment -- -- Data to be Presented at The Obesity Society 2014 Annual Meeting During ObesityWeekSM --
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, October 28, 2014 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of...
- Oct 20, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor...
- Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...
-
Oct 13, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- Oct 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was...
- Oct 1, 2014Findings suggest need for improved education efforts within epilepsy community and beyond to address misperceptions about the disease
Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy patients and caregivers believe the public is...
-
Sep 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- Sep 3, 2014
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"), a subsidiary of Concordia...
- Jun 23, 2014Those Who Take Steps Report Greater Satisfaction with Weight Loss Medications and Surgical Procedures
An analysis of data from the 2012 U.S. National Health and Wellness Survey showed that the majority of those affected by obesity are not taking steps to lose weight (58.4%). The analysis of more...
- Jun 16, 2014
Eisai Inc. announced today that a Phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary...
- Jun 13, 2014Pre-Game Activities Honor Local Epilepsy Awareness Ambassadors
Eisai Inc. announced today it has become a "Keeper of the Flame" sponsor of the Epilepsy Foundation of Metropolitan New York's 2nd Annual Epilepsy Awareness Day which will take place during a...
- Jun 9, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- May 15, 2014Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese
Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment,...
- May 9, 2014Expansion Enables Eisai to Reach 90,000 Healthcare Providers
Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ® to approximately 600, triple the...
- Apr 29, 2014-- Doctors Can Help Patients Set Personal Weight Loss Goals: It's Not a One Size Fits All Approach --
Eisai Inc. today announced the launch of My Healthy™, an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained....
- Apr 25, 2014
Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA™ (perampanel) will be presented at the 66th annual American Academy of Neurology (AAN) meeting, taking place...
-
Apr 14, 2014- Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management -
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy
-
Mar 17, 2014Eisai Supports Epilepsy Foundation as Sponsor of Walk
Eisai Inc. announced today that it is a sponsor of the Epilepsy Foundation's 8th Annual National Walk for Epilepsy in Washington D.C., a...
